Moderna today announced the completion of its biologic license application to the Food and Drug Administration for its mRNA COVID-19 vaccine. The application comes with a request for priority review. Moderna since May has submitted data sections to the FDA on a rolling basis, the complete body of which reviewed its COVID-19 vaccine’s efficacy and safety in more than 30,000 U.S. phase 3 trial participants. Moderna says its final analysis indicates that its vaccine has a 93% efficacy, which persisted through six months after completion of a two-dose regimen.

Related News Articles

Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18. The extension…
Headline
The National Institutes of Health yesterday awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2,…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…
Headline
The Centers for Disease Control and Prevention yesterday released an operational planning guide for pediatric COVID-19 vaccination and preliminary information…
Headline
Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in…
Headline
A Food and Drug Administration advisory panel today voted unanimously to recommend an extra Moderna booster dose for certain individuals. The Vaccines and…